CMC Stock Recent News

Barbara R. Smith to Retire as Executive Chairman Robert S. Wetherbee Appointed Chairman of the Board of Directors Vicki Avril-Groves to Retire from the Board of Directors Tandra Perkins Appointed to the Board of Directors IRVING, Texas , Aug. 2, 2024 /PRNewswire/ -- Commercial Metals Company (NYSE: CMC) ("CMC" or the "Company") today announced that Barbara R.

Ernest Hoffman is a Crypto and Market Reporter for Kitco News. He has over 15 years of experience as a writer, editor, broadcaster and producer for media, educational and cultural organizations.

HUNTSVILLE, AL, July 18, 2024 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. (“Serina”) (NYSE American: SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug delivery technology, today announced the appointment of Dr. Srini Tenjarla as the new Senior Vice President of CMC (Chemistry, Manufacturing, and Controls) and Formulation. Dr. Tenjarla brings over 20 years of extensive experience in drug development to Serina.

Nose-to-Brain Drug Delivery Shows Promising Patient Safety and Therapeutic Benefit The Device and CMC Development Master Plan is designed to support IND-enabling studies SARASOTA, FL, July 18, 2024 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or the “Company”), a developmental stage biopharmaceutical company focused on developing novel formulations and drug delivery systems for traditional therapeutics and psychedelic treatments, today announced it has entered into a Device and CMC Development Master Plan with Resyca BV, a medical technology provider. Resyca is a joint venture between Bespak Group and Medspray Pharma BV which manufactures the formulation-specific microchip-based spray system chosen by Silo for its lead candidate SPC-15, an intranasal prophylactic treatment for post-traumatic stress disorder (PTSD).

Commercial Metals (CMC) gains from strong demand in North America for each of its primary product lines. However, market uncertainties in Europe remain a concern for the company.

VANCOUVER, BC / ACCESSWIRE / June 27, 2024 / CMC Metals Ltd. (TSXV:CMB)(Frankfurt:ZM5P)(OTCQB:CMCXF) ("CMC" or the "Company") is pleased to announce that the Company has completed the final payment on the Blue Heaven Property with the optionor Strategic Metals Ltd.

NEW YORK , June 26, 2024 /PRNewswire/ -- BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of adult stem cell therapeutics for neurodegenerative diseases, today announced it has reached alignment with the U.S. Food and Drug Administration (FDA) on the Chemistry, Manufacturing, and Controls (CMC) aspects of Brainstorm's Phase 3b clinical trial for NurOwn®, its investigational therapy for amyotrophic lateral sclerosis (ALS).     This Type C meeting builds upon the positive momentum established in April 2024, when the FDA granted BrainStorm a Special Protocol Assessment (SPA) agreement for its NurOwn Phase 3b trial.

Commercial Metals' (CMC) Q3 top line primarily reflects the impacts of the ongoing challenging environment in Europe.

Commercial Metals Company (NYSE:CMC ) Q3 2024 Earnings Call Transcript June 20, 2024 11:00 AM ET Company Participants Peter Matt - President and CEO Paul Lawrence - SVP and CFO Conference Call Participants Sathish Kasinathan - Bank of America Tristan Gresser - BNP Paribas Curt Woodworth - UBS Katja Jancic - BMO Capital Markets Timna Tanners - Wolfe Research Alex Hacking - Citi Operator Hello, and welcome everyone, to the Third Quarter Fiscal 2024 Earnings Call for CMC. Joining me on today's call are Peter Matt, CMC's President and Chief Executive Officer; and Paul Lawrence, Senior Vice President and Chief Financial Officer.

Commercial Metals (CMC) came out with quarterly earnings of $1.02 per share, beating the Zacks Consensus Estimate of $1 per share. This compares to earnings of $2.02 per share a year ago.